重组人血小板生成素对白血病化疗后血小板减少症疗效观察

目的:观察重组人血小板生成素(rhTPO)对白血病化疗后重度血小板减少症(≤20×109/L)的疗效和安全性。方法:选15例急性白血病经化疗达完全缓解(CR)后巩固化疗中患者作为治疗组。化疗前血小板计数均≥100×109/L。化疗前1天即开始给予皮下注射rhTPO15000IU,每天一次至骨髓抑制期后血小板恢复。选20例急性白血病巩固化疗中未予rhTPO预防治疗作为对照组。结果:白血病患者化疗后出现重度血小板减少症的时间推迟至化疗后12天,持续时间减少至4~5天,恢复时间提前6天,减少了血小板输注的次数,且仅有不影响治疗的轻微不良反应。结论:rhTPO应用于白血病化疗后重度血小板减少安全而有效。

Recombinant Human Thrombopoietin in Patients with Leukemia after Chemotherapy Thrombocytopenia Curative Effect Observation

Objective: To explore the effect of recombinant human thrombopoietin(rhTPO) on leukemia after chemotherapy of severe thrombocytopenia(< 20 x 109 / L) of the efficacy and safety of.Methods: 15 cases of acute leukemia after chemotherapy achieved complete remission(CR) after consolidation chemotherapy in patients as treatment group.Chemotherapy before platelet counts were > 100 x 109 / L.1 days before chemotherapy was given subcutaneous injection of rhTPO15000IU,once a day to platelet recovery after myelosuppressive phase.20 cases of acute leukemia consolidation chemotherapy in prevention of treatment as the control group without rhTPO.Results: Leukemia after chemotherapy in patients with severe thrombocytopenia in a time delayed until 12 days after chemotherapy,duration reduced to 4 ~ 5 days 6 days ahead of time,recovery time,reducing the number of platelet transfusions,and only does not affect the treatment of minor adverse reactions.Conclusion: The application of rhTPO in patients with leukemia after chemotherapy of severe thrombocytopenia is safe and effective.